1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6FCD94D18119FE02F0025877D00386D08
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-accelerating-launch-success-through-improved-diagnosis-rare-diseases-vyndamax-vyndaqel-blockbuster?opendocument
18
19opendocument
203.89.204.127
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Product Launch Excellence

Accelerating Launch Success through Improved Diagnosis of Rare Diseases: How Vyndamax/Vyndaqel created a blockbuster through faster, easier and more frequent diagnosis of ATTR-CM

ID: 5702


Features:

34 Info Graphics

4 Data Graphics

60+ Metrics

15 Narratives


Pages/Slides: 47


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Accelerating Launch Success through Improved Diagnosis of Rare Diseases: How Vyndamax/Vyndaqel created a blockbuster through faster, easier and more frequent diagnosis of ATTR-CM”

STUDY OVERVIEW

As the first and only medicines approved by the FDA to treat rare disease - ATTR-CM, Vyndamax and Vyndaqel entered the market with powerful outcomes showing improved survival and patient function with lower hospitalizations.

However, considering that ATTR-CM is often difficult to diagnose, Pfizer realized that efficacy alone wasn’t enough to get the much-needed traction for Vyndamax/Vyndaqel launch.

So Pfizer set out to educate the market and aid in early diagnosis of ATTR-CM to uncover a massive growth opportunity. The awareness and diagnosis campaigns helped produce a 683% increase in diagnosed patients, turning a specialty care medicine for a rare condition into an unexpected blockbuster.

Best Practices, LLC produced this case study to uncover the winning strategies and tactics used by Pfizer to create a blockbuster launch for Vyndamax/Vyndaqel through faster and improved diagnosis of rare disease, ATTR-CM.

KEY TOPICS

  • Difficult Diagnosis of Specialty Conditions Can Mask Market Opportunity
  • Pfizer Addressed an Unmet Market Need and Helped Double Correct Diagnosis along the Way
  • How Pfizer Doubled the Market through Faster, Easier, and More Frequent Diagnosis
  • Using Patient Education and Advocacy to Support Better Awareness and Earlier Interventions
  • Pfizer Expanded the Market while Increasing the Correct Diagnosis Rate from Less than 1% to 24% within 2 Years
  • Nurture the Health Ecosystem for Faster Diagnosis and Better Care
  • Lessons Learned and Winning Strategies from Vyndaqel / Vyndamax’s Successful Market Entry

SAMPLE KEY FINDINGS

  • Earlier is Also Better: Pfizer developed its “Suspect & Detect” campaign integrating red flag symptoms and expert recommendations to help earlier identification and intervention of ATTR-CM.
  • Digital Leverage: The revolution in digital communications helped Vyndaqel extend education through video, downloads, interactive exercises, tools, and programs delivered faster and at lower cost.

METHODOLOGY

This case study was created using multiple secondary research sources.

Industries Profiled:
Pharmaceutical; Biotech; Health Care


Companies Profiled:
Pfizer

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.